Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery

Covid19 Clinical Trial

Official title:

Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04480580
• Other study ID #: COVID-SURG
• Status: Completed
• Start date: March 30, 2020
• Est. completion date: June 30, 2020

Study information

• Verified date: July 2020
• Source: University of Cagliari
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We have herein analysed the patients admitted to our Department that underwent serologic tests for SARS-CoV-2 either by Ab or RT PCR, to estimate the prevalence of COVID-19 in the setting of a non-dedicated COVID-19 hospital and in a low CoV-2 incidence area, and to evaluate if security measures are necessary for this context.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: June 30, 2020
• Est. primary completion date: April 30, 2020
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients hospitalized during pandemic spread

Exclusion Criteria:

• Incomplete data

Related Conditions & MeSH terms

• Coronavirus Infections
• Covid19
• SARS (Severe Acute Respiratory Syndrome)
• Severe Acute Respiratory Syndrome
• Surgery

Intervention

Diagnostic Test:
• SARS-CoV-2 Ab
Patient test for specific antibodies for SARS-CoV-2

Locations

Country	Name	City	State
Italy	AOU Cagliari	Cagliari	CA

Sponsors (1)

Lead Sponsor	Collaborator
University of Cagliari

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroprevalence of SARS-CoV-2	Positivity of specific IgM or IgG	3 months